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Estimates of survival and costs are identical for cisplatin-
paclitaxel and cisplatin-gemcitabin. There was a higher
incidence of severe toxicities with cisplatin-gemcitabin,
but differences in QoL are still to be determined. 
Gemcitabin-paclitaxel is a dominated option with higher
costs and non-superior survival.
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OBJECTIVES: Colon cancer is one of the most common
malignancies in developed countries. Surgery is the
primary treatment modality for this disease. However, by
the time the patient presents with recurrent symptoms,
the disease is rarely curable by surgery even when com-
bined with other therapy. The aim was to assess the 
clinical and economic outcomes of OncoVAX®. therapy
in stage II colon cancer patients. METHODS: We have
completed a prospectively randomized, controlled clinical
trial of patients with Stage II colon cancer with active 
speciﬁc immunotherapy (ASI) using autologous tumor
cell with an immunomodulating adjuvant bacillus 
Callmette-Guérin (BCG) vaccine (OncoVAX) in an adju-
vant setting. Patients were randomized to either a control
group or (OncoVAX) therapy, after surgical resection of
the primary tumor and stratiﬁcation by stage of disease.
The cost analysis consisted of the direct health care costs.
For the model, the costs and probabilities of the several
interventions, disease stages and follow-up have been 
calculated. Survival and recurrence free survival were
used from the clinical study. Utility values were derived
from the literature. RESULTS: OncoVAX signiﬁcantly
improved survival and recurrence-free survival. The
number of life years in the OncoVAX group amounted to
6.96 and in the control group 6.17. The number of recur-
rence-free life years gained is approximately 1.14 more in
the OncoVAX group. The average costs per patient in the
OncoVAX group amounted to US$20,395 and in the
control group US$4,958. The costs per life year gained
amounted to US$19,541 and the costs per QALY
amounted to US$20,489. The total discounted cost-
effectiveness ratio was US$22,660 and the discounted
cost-utility ratio amounted to US$23,675 (discount rate:
4%). CONCLUSION: This study shows that OncoVAX
is an effective treatment modality for patients with stage
II colon cancer with a cost-effectiveness ratio in the range
of other oncological treatments.
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OBJECTIVES: Patients undergoing major orthopaedic
surgery are at risk of deep vein thrombosis, pulmonary
embolism and subsequent complications, some of which
may be fatal. For this reason post-operative prophylaxis
is recommended. Enoxaparin is the most frequently used
chemical prophylaxis in the UK. Fondaparinux is a novel
antithrombotic whose efﬁcacy has been demonstrated,
but whose cost-effectiveness has not been assessed. We
evaluated the cost-effectiveness of fondaparinux relative
to enoxaparin over a period of ﬁve years post-surgery.
METHODS: We modeled the impact of fondaparinux 
on patient outcomes and costs to the UK National 
Health Service (NHS). Outcomes are thromboembolitic
events (symptomatic deep vein thrombosis, pulmonary
embolism) and death. Data on the incidence of throm-
boembolitic events were derived from four randomised
clinical trials comparing enoxaparin with fondaparinux,
and from a review of the literature. Resource conse-
quences were estimated from a survey of UK hospitals
and discussions with a panel of clinical experts. Costs
were estimated using mean national costs to the NHS.
RESULTS: Fondaparinux dominates enoxaparin for all of
the surgery groups studied. The number of venous throm-
boembolic events (VTE) averted with fondaparinux is 15
per 1000 procedures (Total Hip Replacement), 19.5/1000
(Total Knee Replacement), 23.3/1000 (Hip Fracture
Surgery) and 19.2/1000 (All Procedures). The number of
VTE-related deaths averted is 0.8/1000 (THR), 0.8/1000
(TKR), 5.9/1000 (HFS) and 3.1/1000 (All Procedures).
Fondaparinux reduces expected cost per patient by £18
(THR), £41 (TKR), £30 (HFS) and £29 (All Procedures).
CONCLUSIONS: Compared with current practice in the
UK, fondaparinux is cost-effective. This conclusion is sen-
sitive to the relative price difference between enoxaparin
and fondaparinux, but it is robust to variations in all of
the other key parameters in the model. We estimate that
using fondaparinux could reduce NHS costs by £3.8
million annually.
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